Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small molecule drug designed using generative AI, to treat idiopathic pulmonary ...

Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results ...

A biotech that uses artificial intelligence to assist its drug discovery efforts has relocated its headquarters from New York ...

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

Ins("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class small molecule ...

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration ...

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with ...